Head to Head Contrast: ANI Pharmaceuticals (ANIP) vs. Its Peers

ANI Pharmaceuticals (NASDAQ:ANIP) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare ANI Pharmaceuticals to related companies based on the strength of its analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Profitability

This table compares ANI Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.22%	28.34%	11.18%
ANI Pharmaceuticals Competitors	-2,380.61%	-219.90%	-15.56%

Risk & Volatility

ANI Pharmaceuticals has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals’ peers have a beta of -3.79, indicating that their average stock price is 479% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for ANI Pharmaceuticals and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0	4	3	0	2.43
ANI Pharmaceuticals Competitors	7806	13897	25803	1039	2.41

ANI Pharmaceuticals currently has a consensus price target of $100.00, indicating a potential upside of 40.35%. As a group, “Pharmaceuticals” companies have a potential upside of 25.38%. Given ANI Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe ANI Pharmaceuticals is more favorable than its peers.

Valuation and Earnings

This table compares ANI Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37 million	$78.34 million	14.19
ANI Pharmaceuticals Competitors	$3.55 billion	$3.18 billion	552.64

ANI Pharmaceuticals’ peers have higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

76.0% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

ANI Pharmaceuticals beats its peers on 7 of the 13 factors compared.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company’s rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.